CD163 and melanoma: In a clinical trial conducted in melanoma pts., has been explored the combination of bevacizumab with anti-CTLA-4 inhibitor, ipilimumab, revealed widespread morphological modifications in CD31+ endothelial cells and an extensive tumor penetration of immune cells post-treatment including CD8+ cells and CD163+ macrophages in comparison to ipilimumab treatment alone, thus demonstrating that the combination of anti-VEGF and anti-CTLA-4 inhibitors has the ability to promote immune cell access in the TME [60].